An Open-label, Phase I, Dose-escalation Study of ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2014
At a glance
- Drugs Naptumomab estafenatox (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Active Biotech Research
- 22 Oct 2014 Last checked against ClinicalTrials.gov record.
- 11 Feb 2006 New trial record.